AI assistant
Adaptimmune Therapeutics PLC — Capital/Financing Update 2015
May 6, 2015
34721_rns_2015-05-05_c345fdd5-01cf-4311-9b07-ad4e4884b3c4.zip
Capital/Financing Update
Open in viewerOpens in your device viewer
F-1MEF 1 a2224633zf-1mef.htm F-1MEF QuickLinks -- Click here to rapidly navigate through this document
COMMAND=ADD_BASECOLOR,"Black" COMMAND=ADD_DEFAULTFONT,"font-family:times;" COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" As filed with the United States Securities and Exchange Commission on May 5, 2015
Registration No. 333-
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" COMMAND=ADDING_LINEBREAK
FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" COMMAND=ADDING_LINEBREAK
ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter)
Not Applicable (Translation of Registrant's name into English)
User-specified TAGGED TABLE
England and Wales (State or other jurisdiction of incorporation or organization) 2836 (Primary Standard Industrial Classification Code Number) Not Applicable (I.R.S. Employer Identification Number)
end of user-specified TAGGED TABLE
91 Park Drive, Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (44) 1235 430000 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" COMMAND=ADDING_LINEBREAK
ADAPTIMMUNE LLC University City Science Center 3711 Market Street8 th Floor Philadelphia, PA 19104 United States of America (267) 499 2066 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" COMMAND=ADDING_LINEBREAK
User-specified TAGGED TABLE
| Copies to: — David S. Bakst Mayer Brown LLP 1221 Avenue of the Americas New York, NY 10020 Telephone: (212) 506 2500 Facsimile: (212) 262 1910 | James J. Noble Chief Executive Officer Adaptimmune Therapeutics plc 91 Park Drive, Milton Park Abingdon, Oxfordshire, OX14 4RY United Kingdom Telephone: (44) 1235 430000 Facsimile: (44) 1235 430001 | Steven D. Singer Lisa Firenze Wilmer Cutler Pickering Hale and Dorr LLP 7 World Trade Center 250 Greenwich Street New York, NY 10007 Telephone: (212) 230 8800 Facsimile: (212) 230 8888 |
|---|---|---|
end of user-specified TAGGED TABLE
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ý 333-203267
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" COMMAND=ADDING_LINEBREAK
CALCULATION OF REGISTRATION FEE
User-specified TAGGED TABLE
| Title of each class of securities to be registered(1) | Amount to be registered(2) | Proposed maximum offering price per share | Proposed maximum aggregate offering price | Amount of registration fee(3) |
|---|---|---|---|---|
| Ordinary shares, par value £0.001 per share | 12,937,500 | $2.83 | $36,656,250 | $4,259.46 |
end of user-specified TAGGED TABLE (1) Each ADS represents six ordinary shares. ADSs issuable upon deposit of the ordinary shares registered hereby are registered pursuant to a separate registration statement on Form F-6 (File No. 333-203642). (2) Represents only the additional number of shares being registered and includes 1,687,500 additional shares, represented by American Depositary Shares, or ADSs, that the underwriters have the option to purchase. In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, the amount being registered does not include the 64,687,500 ordinary shares that the Registrant previously registered on the Registration Statement on Form F-1 (File No. 333-203267). (3) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price and the initial public offering price per ADS. The Registrant previously registered securities at an aggregate offering price not to exceed $183,281,250 on a Registration Statement on Form F-1 (File No. 333-203267), which was declared effective by the Securities and Exchange Commission on May 5, 2015. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $36,656,250 is hereby registered.
COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" COMMAND=ADDING_LINEBREAK
The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
BLANK LINE TO FORCE PARA
ZEQ.=1,SEQ=1,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=182984,FOLIO='blank',FILE='DISK132:[15ZAG1.15ZAG43701]BA43701A.;34',USER='JTAYLORA',CD=';5-MAY-2015;14:10' THIS IS THE END OF A COMPOSITION COMPONENT
COMMAND=ADD_BASECOLOR,"Black" COMMAND=ADD_DEFAULTFONT,"font-family:times;" COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;"
Explanatory Note
This Registration Statement is being filed with respect to the registration of additional securities of Adaptimmune Therapeutics plc (the "Company") pursuant to Rule 462(b) and General Instruction V to Form F-1, both promulgated under the Securities Act of 1933, as amended. The contents of the Registration Statement on Form F-1 (File No. 333-203267) initially filed by the Company with the Securities and Exchange Commission (the "Commission") on April 6, 2015 which was declared effective by the Commission on May 5, 2015 including all amendments, supplements and exhibits thereto and each of the documents filed by the Company with the Commission and incorporated or deemed to be incorporated therein (the "Original Registration Statement"), are incorporated herein by reference. This registration statement is being filed solely to increase the amount of securities offered pursuant to the Original Registration Statement.
The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.
ZEQ.=1,SEQ=2,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=909528,FOLIO='blank',FILE='DISK132:[15ZAG1.15ZAG43701]BB43701A.;11',USER='WWASSER',CD=';5-MAY-2015;16:29' THIS IS THE END OF A COMPOSITION COMPONENT
COMMAND=ADD_BASECOLOR,"Black" COMMAND=ADD_DEFAULTFONT,"font-family:times;" COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;"
TOC_END
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Oxfordshire, England, on May 5, 2015.
COMMAND=ADD_TABLEWIDTH,"100%" User-specified TAGGED TABLE
| /s/ JAMES J. NOBLE | |
|---|---|
| Name: | James J. Noble |
| Title: | Chief Executive Officer |
end of user-specified TAGGED TABLE
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on May 5, 2015 in the capacities indicated.
COMMAND=ADD_TABLEWIDTH,"100%" User-specified TAGGED TABLE
| Position | |
|---|---|
| /s/ JAMES J. NOBLE James J. Noble | Chief Executive Officer and Director (Principal Executive Officer) |
| * Jonathan Knowles, Ph.D. | Chairman of the Board of Directors and Director |
| * Adrian Rawcliffe | Chief Financial Officer (Principal Financial and Accounting Officer) |
| * Lawrence M. Alleva | Director |
| * Ali Behbahani, M.D. | Director |
| * Ian Laing | Director |
| * David M. Mott | Director |
| * Elliott Sigal, M.D., Ph.D | Director |
end of user-specified TAGGED TABLE
ZEQ.=1,SEQ=3,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1012118,FOLIO='blank',FILE='DISK132:[15ZAG1.15ZAG43701]JC43701A.;26',USER='JTAYLORA',CD=';5-MAY-2015;14:12'
COMMAND=ADD_TABLEWIDTH,"100%" User-specified TAGGED TABLE
| Signature | |
|---|---|
| * Peter Thompson, M.D. | Director |
| *By: | /s/ JAMES J. NOBLE James J. Noble Attorney-in-Fact |
end of user-specified TAGGED TABLE
ZEQ.=2,SEQ=4,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=366766,FOLIO='blank',FILE='DISK132:[15ZAG1.15ZAG43701]JC43701A.;26',USER='JTAYLORA',CD=';5-MAY-2015;14:12'
SIGNATURE OF AUTHORIZED UNITED STATES REPRESENTATIVE OF THE REGISTRANT
Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of Adaptimmune Therapeutics plc, has signed this registration statement or amendment thereto on May 5, 2015.
COMMAND=ADD_TABLEWIDTH,"100%" User-specified TAGGED TABLE
| /s/ JAMES J. NOBLE | |
|---|---|
| Name: | James J. Noble |
| Title: | Chief Executive Officer |
end of user-specified TAGGED TABLE
ZEQ.=3,SEQ=5,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1037693,FOLIO='blank',FILE='DISK132:[15ZAG1.15ZAG43701]JC43701A.;26',USER='JTAYLORA',CD=';5-MAY-2015;14:12' THIS IS THE END OF A COMPOSITION COMPONENT
COMMAND=ADD_BASECOLOR,"Black" COMMAND=ADD_DEFAULTFONT,"font-family:times;" COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;"
TOC_END
EXHIBIT INDEX
COMMAND=ADD_TABLEWIDTH,"100%" User-specified TAGGED TABLE
| Exhibit Number | Description of Exhibit | |
|---|---|---|
| 1.1 | (1) | Form of Underwriting Agreement. |
| 5.1 | Opinion of Mayer Brown International LLP as to the validity of the ordinary shares. | |
| 23.1 | Consent of KPMG LLP for Adaptimmune Limited. | |
| 23.2 | Consent of KPMG LLP for Adaptimmune Therapeutics Limited. | |
| 23.3 | Consent of Mayer Brown International LLP (included in Exhibit 5.1). | |
| 24.1 | (2) | Powers of Attorney. |
end of user-specified TAGGED TABLE COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="31%" ALIGN="LEFT"
(1) Previously filed as Exhibit 1.1 to the Registrant's Registration Statement on Form F-1, as amended (File No. 333-203267), originally filed with the Securities and Exchange Commission on April 27, 2015 and incorporated by reference herein. (2) Previously filed on the signature page to the Registrant's Registration Statement on Form F-1, as amended (File No. 333-203267), originally filed with the Securities and Exchange Commission on April 6, 2015 and incorporated by reference herein.
ZEQ.=1,SEQ=6,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=42760,FOLIO='blank',FILE='DISK132:[15ZAG1.15ZAG43701]JE43701A.;48',USER='JTAYLORA',CD=';5-MAY-2015;14:12' THIS IS THE END OF A COMPOSITION COMPONENT
QuickLinks
TOC_BEGIN SIGNATURES SIGNATURE OF AUTHORIZED UNITED STATES REPRESENTATIVE OF THE REGISTRANT TOC_BEGIN EXHIBIT INDEX SEQ=,FILE='QUICKLINK',USER=BFLANNO,SEQ=,EFW="2224633",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1" TOCEXISTFLAG